Press Releases

NEW YORK, Sept. 4, 2019 /PRNewswire/ -- Kallyope Inc., a leading biotechnology company focused on identifying and pursuing therapeutic opportunities involving the gut-brain axis, today announc

PLANO, Texas, Sept. 4, 2019 /PRNewswire/ -- Jeffery Bullard, MD, a trailblazing physician and health care entrepreneur and innovator, has been named the new Chief Medical Officer for the Catalyst Health Network.

MANHASSET, N.Y., Sept. 4, 2019 /PRNewswire/ -- The Public Library of Science Magazine, known as PLOS Biology, notes 26 Feinstein Institutes researchers in a paper assessi

ATLANTA, Sept. 4, 2019 /PRNewswire/ -- Healthcare Workforce Logistics (HWL), the nation's innovator and leader in vendor neutral workforce solutions, has been engaged to manage

LOS ANGELES, Sept. 4, 2019 /PRNewswire/ -- For the first time in American history, U.S. landmarks in all 50 states (and the District of Columbia) were lit blue on September 3 to kick-off Prostate Cancer Awareness Month. The Prostate Cancer Foundation's (PCF) "Light It Blue" campaign is a national effort

WEST ORANGE, N.J., Sept. 4, 2019 /PRNewswire/ -- Parents place their faith in the education system for not only learning but also for nurturing and development of their children. The role of teachers in shaping America's future cannot be overestimated. "Teachers are under increasing stress and are not immune from turning to alcohol or drugs in order to cope with stresso

NASDAQ, TSX: NVCN VANCOUVER, Sept. 4, 2019 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that

STOCKHOLM, Sept. 4, 2019 /PRNewswire/ --  Cyxone (publ), a Swedish biotechnology company in autoimmune diseases, today announced that the company's board of directors has decided to explore the possibilities of an orphan drug designation (ODD) of the drug candidate Rabeximod. An orphan drug status would mean that the drug candidate obtains a strengthened positio

MENLO PARK, Calif., Sept. 4, 2019 /PRNewswire/ -- Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced the closing of $31 million in Series D Preferred Stock financing led by KCK Group, a leading investor in hig

NEW YORK, Sept. 4, 2019 /PRNewswire/ -- Research Foundation to Cure AIDS (RFTCA) has obtained a worldwide license to biotechnology known as Chromovert® Technology, to research, develop and commercialize a cure for HIV/AIDS. This is the first and only case of an IRS Code § 501(c)3 not-for-profit organizat